glp 1 for non obese What is the pipeline future medications for obesity? Long-term Success of GLP-1s Hinges

Notably, a key feature of this approval is its link to the FDAs National Priority Voucher (CNPV) program

doi: 10.1016/j.numecd.2021.08.039

Key end points included: hospitalisation, heart failure (ICD-10-CM-I50), myocardial infarction (ICD-10-CM-I21), stroke and transient ischaemic attack (ICD-10-CM-I63, G45), development of diabetic microvascular complications (ICD-10-CM-E10.210.4) and all-cause mortality analysed 3 months to 5 years post drug initiation

Given the intractable pediatric obesity epidemic and associated rise in type 2 diabetes in youth, made worse by the COVID-19 pandemic related shutdowns and disruptions in opportunities for exercise and play in youth, this new class of medications will certainly benefit children with morbid obesity and type 2 diabetes

Frequently Asked Questions (FAQs) Is Ozempic available in India